BusinessSummit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 TrialBy Nasdaq OMXMar 7, 2016, 12:00 PM UTC
BusinessSummit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease SymptomsBy Nasdaq OMXFeb 24, 2016, 12:00 PM UTC
BusinessSummit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile InfectionBy Nasdaq OMXJan 19, 2016, 12:00 PM UTC
